Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

TLR7 agonist RO7119929

An orally bioavailable Toll-like receptor (TLR) 7 agonist, with potential immunostimulating and antitumor activities. Upon oral administration, TLR7 agonist RO7119929 targets, binds to and activates TLR7. This may trigger the activation of cluster of differentiation (CD) 8-positive T cells, B cells, and innate immune cells including natural killer (NK) cells and macrophages, and may induce the production of cytokines including interferon alpha (IFNa), leading to antitumor activity. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	RO 7119929 RO-7119929 RO7119929

TLR7 agonist RO7119929

Search NCI's Drug Dictionary